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 Wounds in the mouth, occurring after oral surgery, take time to heal.  No ointment can be 
added to help with the healing process because mouth saliva will constantly wash it away.  In 
order to combat this problem, we propose engineering a normal flora microbe to grow at the site 
of injury and secrete a recombinant growth factor to promote healing of the damaged tissue.  Our 
goal is to have the yeast Pichia pastoris produce human basic fibroblast growth factor (bFGF), 
which aids in cellular proliferation.  P. pastoris is a good choice for this application because not 
only is it considered generally recognized as safe (GRAS) by the FDA, but it is a eukaryote that 
is able to perform posttranslational modifications and secrete large amounts of recombinant 
protein.  
Previous studies have shown that a strain of P. pastoris can be engineered to express 
bFGF from a methanol-sensitive promoter.  The study also showed that the bFGF, which was 
purified from the yeast’s extracellular medium, was able to promote the growth of NIH/3T3 cells 
(mice fibroblasts).  Because we needed the P. pastoris to express the bFGF in glucose –based 
tissue culture medium in the presence of mammalian cells, we expressed the bFGF from the 
constitutive promoter GAP promoter.  Along with optimizing and characterizing expression of 
bFGF, we also investigated the effect of the recombinant protein on mammalian cell growth 
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using both scratch ad MTS assays.  In addition, the effects of the yeast being co-cultured with 
mammalian cells was studied.  Our results provide a basis for how a recombinant protein can be 
clinically used to improve wound healing in the mouth using a yeast strain to produce and secrete 
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Chapter 1: Introduction 
Healing of Oral Injuries 
Wounds in the mouth, whether from a surgery or an injury, take some time to heal.  For 
example, the gums from teeth extractions take 1 week to initially close and up to 8 weeks for the 
extraction cavity to be filled with bone (Politis, Schoenaers, Jacobs, and Agbaje, 2016).  Within 
that time frame, a host of problems can arise such as dry socket and infection (Politis, 
Schoenaers, Jacobs, and Agbaje, 2016).  Dry socket is when the blood clot of an extracted tooth 
gets dislodged, dissolves, or never forms before the wound is healed, exposing underlying bone 
and nerves which is extremely painful.  In addition, a bacterial infection can happen anytime 
there is an opening in our tissue, which would mean that the longer the wound is present, the 
more likely there will be a bacterial infection.  Topical ointments that can promote healing are 
not effective when applied to the injured oral site because the constant production of saliva will 
simply wash it away, rendering the ointment ineffective.  We will try to tackle this problem by 
creating a product containing a strain of yeast that will be able to adhere to the site of injury and 
constitutively secrete a recombinant growth factor to accelerate the healing of the damaged tissue 
so that no further complications can arise. 
Recombinant Protein 
 The introduction of genetic engineering has opened the door to the world of recombinant 
proteins, such as antibodies, enzymes, and vaccines.  These products are made in host cells, such 
as bacteria or yeasts, that normally do not produce these proteins.  This process called 
heterologous protein expression has become a multibillion-dollar market (Gomes et al., 2012). 
Because of this, many advances in this technique have been made, but the basics for 
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heterologous protein expression start with identifying the gene that encodes for the protein of 
interest.  Then, a cDNA is made from the respective mRNA.  The cDNA is then inserted into a 
vector (bacteriophage, plasmid, or virus) which delivers the cDNA to a suitable host including 
bacteria (Baneyx, 1999), yeast (Cregg et al., 2000), and mammalian cell (Rosser et al., 2005) 
cells.  That host will then express the desired protein from the cDNA that was transformed into it 
after transcription and translation.  The proteins will then be purified and collected in order to 
use or sell.  The steps of this process vary for each protein depending on the expression vector 
and host. 
Bacterial Host Protein Expression System 
 The first system for foreign protein expression was done in bacteria, or more specifically, 
in Escherichia coli (E. coli) (Chen, 2011).  This system is generally favored for it is easy to 
genetically manipulate, has a doubling time of only 30 minutes, and is generally easy to grow in 
lab conditions.  Even though this protein expression system may be efficient, E. coli has its 
limitations on what kinds of proteins can be produced due to the fact that it is a prokaryote. 
Many prokaryotes have difficulty or are incapable of performing many complex post-
translational modifications such as disulfide bond formation and glycosylation.  This is mainly 
because prokaryotes do not have any membrane bound organelles that can make post-
translational modifications like the endoplasmic reticulum (ER) or the Golgi apparatus (Choi et 
al., 2003).  Some proteins require these modifications in order to be fully functional because 
post-translational modifications control charge, solubility, folding, correct cellular targeting, and 
immunogenicity (Walsh and Jefferis, 2006).  
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 Another limitation to what E. coli can do lies in the purification of the desired protein. 
When E. coli produces the target protein, the protein generally is retained within the cell inside 
the cytoplasm (Sahdev et al., 2007).  Not only is lysing the cells necessary, but many endogenous 
proteins from the E. coli will be present so many steps are required to isolate the foreign protein 
of interest.  Not only will this system bring up the cost and time to purify the desired protein, but 
there will a significant loss of the protein during the many steps to purification (Sahdev et al., 
2007).  Recombinant proteins isolated from E. coli also contain endotoxins as it is a part of a 
Gram-negative cell wall.  Endotoxins can lead to inflammation and other problems if the protein 
is taken internally (Suffredni et al., 1999). 
Yeast Recombinant Protein Expression System 
 Yeast protein expression systems have been successful systems for many years with the 
development of genetic engineering tools (Gomes et al., 2018).  There is a large variety of yeast 
expression hosts that are used such as Saccharomyces cerevisiae (S. cerevisiae), Pichia pastoris 
(also known as Komagataella phaffii), Kluyveromyces lactis, and Yarrowia lipolytica (Gomes et 
al. 2018).  Yeasts are often used as hosts to express certain proteins because they are simple 
eukaryotes which can do post-translational modifications (Mu et al., 2007).  Yeast cells are also 
physically robust, so they are easy to cultivate (Mu et al., 2007).  Lastly, because yeasts do not 
secrete a lot of their own proteins, do not have endotoxins, and are not subject to bacteriophage 
contamination, recombinant protein purification does not require many costly and time-
consuming steps (Cereghino and Cregg, 1999).  Because of these reasons, yeasts are used as 
hosts to express a large variety of recombinant proteins such as chemicals, fuels, food, and 
pharmaceuticals (Gomes et al., 2018). 
18 
 
Pichia pastoris as a Recombinant Protein Expression System 
The methylotrophic yeast (yeast that can reduce 1 carbon compounds as the carbon 
source for their growth) Pichia pastoris (P. pastoris) has several advantages as a host.  Although 
S. cerevisiae is the dominant yeast species chosen for heterologous expression, P. pastoris has 
achieved a very high level of success in producing over 5,000 recombinant proteins, including 
industrial enzymes and biopharmaceuticals (Safder et al., 2018).  These P. pastoris produced 
peptides are less likely to be immunogenic and inactive than those made in S. cerevisiae since P. 
pastoris does not hyperglycosylate its proteins (Ahmad et al., 2014). P. pastoris prefers 
respiratory growth over fermentation and does not produce ethanol. Because of the absence of 
this toxic alcohol, P. pastoris can reach a higher cell density than baker’s yeast to produce more 
of the desired recombinant protein.  In addition, P. pastoris does not secrete as many endogenous 
proteins as S. cerevisiae; therefore, purification of the secreted desired protein can be done much 
easier with P. pastoris (Faber et al., 1955).  It was even found, in one instance, that up to 80% of 
the total protein secreted into the extracellular medium was the foreign recombinant protein 
(Montesino R. et al., 1998). 
Another reason for using the yeast P. pastoris is because the members of the genus 
Pichia are found to be a part of the normal flora in the human mouth (Hunter et al., 1998).  This 
is very important because introducing a new species of microorganism into an environment that 
normally does not have it can cause the new microbe to outcompete the ones that are already 
there, causing an overgrowth of the introduced species.  This can result in many health problems. 
An example of this would be oral thrush, an overgrowth of the fungus Candida albicans.  Oral 
thrush causes creamy white lesions, redness, burning, and soreness that may be severe enough to 
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cause difficulty eating (Singh et al., 2014).  Therefore, introducing Pichia to the mouth should 
not be a problem since it is already part of the mouth’s microbial ecosystem.  
Lastly, another advantage of using P. pastoris is that the Food and Drug Administration 
(FDA) recognizes P. pastoris as GRAS (generally recognized as safe).  P. pastoris was also 
originally developed and used as a source of high protein animal feed for livestock.  Now, 
several products made by P. pastoris have been approved by the FDAfor uses as therapeutic 
proteins, such as Kalbitor®, a kallikren inhibitor (Ciofalo, 2006; Thompson, 2010).  This is 
useful to our long-term goal because the yeast will need to be inside of the oral cavity to do its 
work and will need to be safe for human consumption. 
Pichia pastoris Promoters 
Since P. pastoris is a methylotrophic yeast, it has a very tightly regulated alcohol oxidase 
(AOX1) promoter which is used to provide a high level of heterologous proteins (Cregg et al. 
1985).  It is a methanol induced promoter that can be used to control the production of the 
desired recombinant protein.  When in methanol, the promoter is transcribed about 1,000 times 
faster than if the yeast was grown in glucose (Cregg et al. 1985).  A common application of this 
promoter is when the desired protein being made is toxic to the yeast cells (Yang et al., 2018). 
Thus, cells are grown in glucose to accumulate biomass but inhibit expression of the 
recombinant protein and then switched to methanol to trigger production of the desired protein. 
This way, the large biomass will be able to produce a large quantity of the recombinant protein. 
Although this promoter has many advantages, we will not be using the AOX1 promoter in this 
project since methanol is not present in the human mouth and we want the growth factor to be 
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constitutively expressed and secreted. The promoter that will be used here is the glyceraldehyde-
3-phosphate dehydrogenase (GAP) promoter.  
The GAP promoter is a strong and constitutive promoter, meaning it is transcribed at a 
consistent rate and leads to the production of a lot of target protein on many different nutritional 
media (Qin et al., 2011).  The GAP promoter is active in the presence of glucose or glycerol and 
has been observed to be more efficient than the AOX1 promoter for certain proteins like 
Tribolium castaueum carboxylesterase (TCE) (Zhang et al., 2009).  We will be using the GAP 
promoter, which will be accompanied by a ZeocinTM resistance gene as well as a MATα secretion 
signal in the protein expression vector (pGAPZαB).  
Protein Secretion 
 It is generally easier to purify a protein from the extracellular meddium than from the 
cytoplasm of a host cell, such as P. pastoris.  This protein export eliminates the need to do high-
cost and low yielding cell disruption to obtain the desired protein.  To be delivered into the 
extracellular medium, a protein must transit the secretory system of the yeast.  The protein 
secretory pathway of a eukaryote has a few key steps (Lodish et al., 2000).  When proteins with 
ER targeting signals get synthesized by ribosomes, they are transported into the ER where N-
glycosylation, folding, and cleaving occurs.  From there, the proteins get sent to the Golgi 
apparatus to be further modified and packaged into secretory vesicles that bud out from this 
organelle.  Finally, these vesicles fuse with the plasma membrane to release the protein.  They 
are then either retained in the periplasm, integrated into the cell wall, or released into the 
extracellular matrix (Haguenaur-Tsapis, 1992) The protein follows this route only if it has a 
secretion leader attached.  Many recombinant proteins made by P. pastoris get secreted out of 
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the yeast’s cells by using a S. cerevisiae MATα prepro signal leader peptide (Lin-Cereghino and 
Cregg, 2000).  The pre-region of the MATα signal leader is cleaved at the ER and then the 
remaining pro-region is removed in the Golgi (Kjeldsen, 2000).  The protein then will be 
secreted out of the cell free of any extraneous peptides.  The gene of interest in this project will 
be cloned into the pGAPZαB vector at the C-terminal end the MATα sequence in order for it to 
reach the extracellular medium.  This vector also has the ZeocinTM selectable marker, the 
restriction sites EcoRI and SalI, and the GAP promoter. 
Engineered Probiotic Organisms 
 Probiotics have been used for thousands of years to improve the body’s overall health 
(Schrezenmeir and Vrese, 2001).  Probiotics is an umbrella term for organisms and substances 
which contribute to intestinal microbial balance (Parker, 1974).  In order for a microbe to be a 
probiotic, it must be certified GRAS by the FDA so that they are safe for human consumption. 
These are often administered orally and are an attractive alternative to drugs for intestinal 
diseases (Steidler, 2003).  Lately, probiotics have been used as a drug delivery system for the 
digestive tract (Hudson et al., 2014).  This is done by genetically modifying cells to produce 
proteins or chemicals that the probiotics typically do not make.  This is beneficial because when 
they are in the human body, the engineered probiotic can make the necessary drug to treat the 
human’s digestive tract ailments.  This system is very attractive because it could permit lower 
drug dosage since the probiotic is interacting with the mucosal immune system itself (Hudson et 
al., 2014).  Genetically engineered probiotics should also be less expensive than other delivery 
mechanisms such as nanoparticles and liposomes since bacteria and yeasts can be grown in large 
quantities easily (Hudson et al., 2014).  
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 Heterologous protein expression has successfully been done with the yeast 
Saccharomyces boulardii (S. boulardii). S. boulardii is a probiotic used to treat antibiotic-
induced diarrhea that is caused by Clostridium difficile overgrowth, inflammatory bowel disease, 
and other gastrointestinal disorders (McFarland, 2010).  An example of a recombinant protein 
produced by S. boulardii was human lysozyme, which is beneficial for human gut health (Liu et 
al., 2016).  This lab was able to make this protein using CRISPR-Cas9.S. boulardii was chosen 
over bacterial probiotics because S. boulardii is a eukaryote so it is capable of post translational 
modifications and producing more complex compounds.  S. boulardii was also found to be more 
tolerant of higher temperatures and lower pH found in the digestive tract than other yeasts 
species such as S. cerevisiae (Edwards-Ingram et al., 2007).  Lastly, S. boulardii does not 
colonize the gastrointestinal tract of human which is needed for accurate drug dosing and easy 
clearance of the yeast from the intestine (Blehaut at al., 1989).  Our P. pastoris is similar in that 
it is GRAS and will be used as a drug delivery system to secrete the growth factor at the site of 
injury in the oral cavity. 
Basic Fibroblast Growth Factor 
 Our goal is to use P. pastoris as a drug delivery system for basic fibroblast growth factor 
(bFGF), a 146 amino acid long eukaryotic protein that acts as a growth factor/signaling protein. 
Depending on the posttranslational modifications, the size of the protein can be 18, 22, 23, or 24 
kDa in the human body.  bFGF has a broad variety of functionality.  These pleiotropic effects 
include being a known mitogen that influences chemotaxis, cell differentiation, proliferation, and 
tissue regeneration.  Tissue regeneration includes that of cartilage, skin, cornea, eardrum, 
periodontal, and bone.  Because bFGF is a eukaryotic protein, using bacteria to heterologously 
express bFGF would not likely be successful since the protein needs to be folded correctly as 
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well as receive post-translational modifications, which prokaryotes, like bacteria, cannot do 
reliably.  The posttranslational modifications of bFGF are still quite a mystery.  The only one 
identified is the demethylation of arginine which takes place in glycine-arginine blocks of the N-
terminal (Patry et al., 1994).  
bFGF is made by many tissues, but mostly in human adipocytes (NCBI, 2019).  bFGF 
affects both proliferation and migration of cells.  When bFGF binds to its receptor (bFGFR) of a 
fibroblast, the receptor will stimulate PI3-kinase which will then upregulate GTPase Rac1.  Rac1 






Figure 1: The cell signaling pathway for bFGF to cell migration in a fibroblast cell. (Kanazawa 






P. pastoris Made bFGF  
 Scientists have previously engineered a strain of P. pastoris that can produce the bFGF, 
but they did it using the AOX1 promoter (Mu et al., 2008).  They were able to clone the bFGF 
sequence into the pPICZαA expression vector and transform it into the yeast.  It was found that 
the optimal bFGF production occurred in yeast cells growing at pH5 for 72 hours in a methanol 
concentration of 0.5% (Mu et al.,2008) 300 mg was purified from 2 L of cultivation broth (Mu. 
et al., 2008).  The recombinant bFGF was then tested for biological activity in growing 
mammalian cell, specifically NIH/3T3 cells (mouse fibroblast cells) in an MTT assay.  An MTT 
assay is a colorimetric assay that uses metabolic activity to measure viable cells.  MTT is a 
tetrazolium dye that gets reduced by the cell’s NAD(P)H-dependent cellular oxidoreductase 
enzyme to the insoluble form, formazan.  Formazen is colored so the more cells there are, the 
more the tetrazolium dye gets reduced, the more formazan there is to observe.  A plate reader is 
used to quantitate the absorbance of formazen.  The higher the absorbance, the more viable cells 
there are.  We will follow a similar strategy to express bFGF, except the GAP promoter will be 
used instead of the AOX1 promoter.   
Goal 
 The overall goal of this project is to create a strain of P. pastoris that will be able to co-
exist with mammalian cells as well as secrete the protein bFGF constitutively to enhance the 
growth of these model animal cells.  In order to do this, we will need to generate a heterologous 
expression of bFGF in P. pastoris and test the effects of the bFGF on mammalian cell cultures. 
We will first co-culture the yeast with the mammalian cells to see the overall effects of the total 
secretion products on the cells.  Then, we will purify the bFGF protein using the cation exchange 
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and test the isolated bFGF on mammalian cells.  This project aims to engineer a novel probiotic 



















Chapter 2: Materials and Methods 
Strains, Media, and Reagent 
 TOP10.  The Escherichia coli (E. coli) TOP10 strain from Invitrogen Corp. (Carlsbad, 
CA.) was used for recombinant DNA manipulation and replication.  TOP10 cells were cultured 
in Lennox Broth (LB) medium (0.5% yeast extract, 1% glucose, and 0.5% NaCl) supplemented 
with 25μg/mL kanamycin (kan) or plated on LB+kan plates.  Bacterial cultures were incubated 
and shaken in a New Burnswick Scientific C25 Incubating Shaker (Edison, NJ) at 37°C. 
Bacterial plates were incubated at 37°C. 
 yJC100.  The yJC100 Pichia pastoris (P. pastoris) strain, used in much of this work, is a 
derivative of the original wild type P. pastoris strain NRRLY11430 from North Regional 
Research Laboratories, US Department of Agriculture (Peoria, IL).  This strain of yeast was used 
for protein expression and secretion of the basic fibroblast growth factor (bFGF).  yJC100 was 
generally cultured in yeast extract peptone dextrose (YPD) medium (1% yeast extract, 2% 
peptone, and 2% glucose) supplemented with 100μg/mL ZeocinTM (Zeo) or plated on YPD+Zeo 
plates.  Yeasts were also cultured in Dulbecco’s Modified Eagle Media (DMEM) from 
Biological Industries (Cromwell, Connecticut), a serum-free media with amino acids, vitamins, 
supplementary components, and glucose.  Other media includes Dulbecco’s Modified Eagle 
Media with fetal bovine serum (DMEM+ 10%FBS), Dulbecco’s Modified Eagle Media with calf 
serum (DMEM+ 10%CS), buffered minimal dextrose (BMD, 20% 1M KPi Buffer, 10% Yeast 
Nitrogen Base with ammonium sulfate and without amino acids, 0.02% biotin, 10% dextrose), 
and buffered Dextrose-complex Medium (BMDY, 2% dextrose, 2% peptone, and 1% yeast 
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extract).  Yeast cultures were incubated and shaken in a New Burnswick Scientific C25 
Incubating Shaker (Edison, NJ) at 28°C.  Yeast plates were incubated in at 30°C.  
 The pCMV3-Myc-bFGF plasmid was from Sino Biological Inc. (Beijin, China).  The 
forward and reverse primers for the PCR were purchased from Sigma Genosys (Plano, Texas). 
The antibody mouseαbFGF and the mouseαMyc, antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, California).  The antibodies mouse αJNK/pJNK/GAPDH were 
purchased at Cell Signaling Technology (Danvers, Massachusetts).  All restriction enzymes and 
their respective buffers were purchased from MBI Ferments (Hanover, MD).  Optical densities 
of yeast cultures were measured with Spectronic Genesys 2 (Spectronic Instruments Inc. 
Rochester, NY).  The DNA and protein concentrations were measured at 260 nm and 280 nm, 
respectively, using the Nano Drop 2000c (Thermo Scientific, Wilmington, DE).  
 NIH/3T3.  These mouse fibroblast stem cells were obtained from ATCC (Manassas, 
Virginia).  These cells were used for the scratch and MTS activity assays to test the biological 
activity of bFGF.  These cells are cultured in DMEM and DMEM+CS and incubated at 37°C 
with CO2.  
BioInformatics 
 Generation of DNA sequences, DNA primers, and restriction digest maps were 
performed on SnapGene (Chicago, Illinois). 
Polymerase Chain Reaction (PCR) 
Oligonucleotides were first designed with SnapGene and then synthesized by Sigma 
Genosys (Planto, Texas).  Once the oligonucleotides were obtained, 5μL of each forward and 
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reverse primers were diluted to a concentration of 100ng/μL and added to 5μL of 10x PCR 
buffer, 10μL 5x buffer enhancer, 2μL dNTPs solution, 17.7μL of sterile MilliQ water, and 0.3μL 
of Taq DNA polymerase all in a 0.5 ml Eppendorf PCR tube, using the kit components provided 
by the MasterTaq kit from 5 Prime (San Francisco, California).  PCR was carried out in a 
Applied Biosystems 2720 Thermal Cycler (Foster City, California).  For the first cycle, the PCR 
tube was incubated 95°C for 5 minutes.  Then, for cycles 2-35, the tube was incubated at 95°C 
for 1 minute, 53°C for 1 minute, and 72°C for 1 minute each cycle.  Lastly, the tube was 
incubated at 72°C cycle for 10 minutes and left at 4°C cycle until the tube was taken out.  
Plasmid Miniprep 
 Plasmid DNA was extracted and purified using the Zyppy Plasmid Miniprep Kit from 
Zymo Research (Irvine, CA).  Using the overnight liquid culture of the transformed bacterial 
cells, 1.5 mL were transferred to a 1.5 mL Eppendorf tube, which was spun down in a centrifuge 
at 16,000xg for 2 minutes to pellet the cells.  The supernatant was discarded and the pellet was 
resuspended in 600μL of sterile MilliQ water.  100μL of 7x Lysis Buffer was added and the tube 
was inverted 6-7 times.  350μL of cold Neutralization Buffer was added and mixed by inverting 
the tube 3-4 times (until all the blue turned yellow).  The tube then was centrifuged again at 
16,000xg for 4 minutes so that a pellet of cells, proteins, and chromosomal DNA formed at the 
bottom, leaving the plasmid DNA in the supernatant (~1000μL).  The supernatant was 
transferred to a Zymo-Spin column/collection tube and spun in a centrifuge at 16,000xg for 30 
seconds.  The flow through that in the collection tube was discarded, and 200μL of Endo-Wash 
buffer was added to the spin column and centrifuged at 16,000xg for 30 seconds.  The flow 
through was once again discarded, and 400μL of Zyppy Wash Buffer was added to the spin 
column and centrifuged at 16,000xg for 1 minute.  Afterwards, the spin column was transferred 
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to a new, clean 1.5 mL Eppendorf tube with 30μL of Elution Buffer added to the column.  The 
tube was centrifuged for 30 seconds to collect the eluted and purified plasmid DNA.  
DNA Clean and Concentrate  
Digested pDNA was cleaned and concentrated using the Zyppy DNA Clean and 
Concentrator Kit from Zymo Research (Irvine, CA).  The digested DNA was added to a volume 
of DNA Binding Buffer that was 2x the volume of the sample.  After the solution was transferred 
to a new Zymo-Spin column with a collection tube underneath, it was spun down in a centrifuge 
at 16,000xg for 30 seconds, and the flow through was discarded.  200μL of Wash Buffer was 
added to the column, spun down at the same speed for 30 seconds, and the flow through was 
discarded.  The washing step was repeated two more times.  The column was then transferred to 
a new, clean 1.5 mL Eppendorf tube and 20μL of Elution Buffer gets added to the column.  The 
column is then spun at 16,000 xg for 30 seconds to elute the cleaned, concentrated DNA.  
Restriction Enzyme Digest 
The concentration of the DNA was measured using the Nanodrop 2000c.  A specified 
amount, usually 500ng of DNA, was digested in a 1.5ml Eppendorf tube. 0.5μL of the restriction 
enzyme(s) are added to the DNA, along with the appropriate 10x restriction enzyme buffer 
(MBI, Fermentas, Hanover, MD, etc.).  Sterile MilliQ water was added to bring the total volume 
up to 30μL.  The reaction was then incubated in a 37°C water bath for 1-2 hours.  
Agarose Gel Electrophoresis 
Pre-made 1.2% agarose Flash gels (Lonza, Rockland, ME) were used for running and 
detecting DNA. 2μL of 5x DNA loading dye (50% glycerol, 0.25% bromophenol Blue, 0.35% 
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xylene cyanol, 0.01% SDS, 10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) was added to 8μL of each 
DNA sample.  6μL of each sample was loaded into a well of the Flash gel along with 5μL of 1Kb 
Plus ladder from ThermoScientific (Waltham, Massachusetts).  The proteins were 
electrophoresed at 275 V for 7 minutes and then visualized using the ChemiDoCTM XRS+ 
System from Bio-Rad (Hercules, CA).  
DNA Sequencing 
Approximately 600ng of all purified and concentrated DNA were sent out to Quintarabio 
(Richmond, CA) for sequencing in a new and clean 1.5ml Eppendorf tube.  
Ligation 
 A 3:1 molar ratio of insert and vector was needed for a ligation.  The insert, vector, and 
sterile water were mixed in a 1.5 mL Eppendorf tube and heated at 65°C for 2 minutes and then 
put on ice for 5 minutes.  Next, 2μL of 10x Fermentas ligase buffer (Hanover, Maryland) and 
1μL of Fermentas T4 DNA ligase (Hanover, Maryland) were added to the tube.  Sterile water 
was added to bring up the final volume to 20μL.  The reaction was spun down and mixed before 
letting it incubate at room temperature for at least 3 hours. 
Bacterial Transformation  
Using a heat shock technique, 50μL of competent bacterial cells (OneShot TOP10) Purchased 
from Invitrogen Corp. (Carlsbad, California) were put into a sterile 1.5mL Eppendorf tube.  5μL 
of plasmid DNA or ligation mix was added to the competent cells and incubated on ice for 30 
minutes.  The tube was then taken out and placed into a 42°C water bath for 30 seconds to heat 
shock the cells.  After the heat shock, the tube was rapidly transferred onto ice for 1-2 minutes. 
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245μL of LB was added to the tube, which was placed in a 37°C water bath for 20-60 minutes. 
The transformation mix was then plated onto an LB+(appropriate antibiotic) plates and incubated 
overnight in a 37°C incubator.  
Yeast Transformation 
Using an electroporation technique, 40μL of electrocompotent P. pastoris cells and 4μL 
of linearized plasmid DNA were aliquoted into a cold 2.0mm electroporation cuvette and 
incubated on ice for 5 minutes.  Afterwards, the cuvette was wiped down with a kimwipe and 
placed into the chamber of the BTX ECM 630 Electroporator from Harvard Apparatus 
(Brookline, MA).  The pulse parameters were set at 200Ω, 1500V, 50μF, and 2.0mm. 
Immediately after pulsing, 50% sorbitol in YPD (500μL sorbitol and 500μL YPD) were added to 
the cuvette, and the transformation reaction was subsequently transferred to a 1.5mL Eppendorf 
tube.  After the cells were allowed to recover at 30°C for 1 hour, they were plated on 
YPD+appropriate antibiotic and incubated for 3 days until colonies appeared. 
bFGF Expression Plasmid Construction 
 A plasmid with the desired protein coding sequence was purchased.  The purchased 
plasmid was then transformed into One Shot TOP10 cells to replicate the plasmid.  A plasmid 
miniprep was done to extract the plasmids.  The plasmids were then run through a PCR which 
replicated the desired protein’s coding sequence as well as add on restriction sites on the ends.  A 
restriction digest was done on both the vector the plasmid was designed to go into as well as the 
PCR product.  The ligation protocol was then used to ligate the two pieces together.  
Small Scale Expression in 96 Well Plates 
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  Cells were grown in a sterile 96 deep well plate (DWP) format for enzymatic assays 
(Weis et al, 2004).  Five hundred microliters of sterile water was added to the perimeter of the 
plate to prevent evaporation.  Next, 250 µL of BMD 1X (buffered minimal dextrose 1%; 1 M 
K2HPO4 and 1 M KH2PO4 with pH 6.0, 10X YNB, 500X of 0.02% biotin, and 10X dextrose) 
liquid medium, along with any amino acid supplements if needed, was added into the wells that 
were designated to hold the cell cultures.  Isolated colonies were selected from fresh plates and 
inoculated into their designated wells containing BMD 1X.  Parafilm was wrapped around the 
edges of the DWP and the corners were taped to block evaporation.  The DWP was placed into 
the 29oC shaking incubator at 325 rpm.  After 48 hours, 5 µL of cell culture from select random 
wells were added onto glucose test strips to confirm that all the glucose had been exhausted.  
Subsequently, the cells were induced with 250 µL of 2X BMDY, making the final dextrose 
concentration 1%. The plate was sealed with Parafilm and placed back into the shaking incubator 
with the same settings for 24 hours.  On the next day, the cells were harvested into 1.5 mL 
microcentrifuge tubes.  The OD600 of each sample were measured with a 1:20 dilution.  The 
samples were extracted from the wells into 1.5 mL microcentrifuge tubes and spun down at 
maximum speed for 1 minute and either stored in the -80oC freezer or used immediately. 
Protein Concentrator  
Th protein Centrifugal Filter Units (Milipore, Hayward, California) was washed with 3 
mL of sterile water.  It was spun at 1200 rpm for 10 minutes.  After centrifugation, the flow 
through was discarded.  3 mL of protein was placed into the concentrator and spun again at 1200 
rpm for 10 minutes.  These steps were repeated until all of the samples were gone and the 
volume remaining was down to 500μL.  The 500μL was transferred into a new and clean 1.5mL 
Eppendorf tube.  
33 
 
Spot Western Blot 
75μL-200μL of sample were spotted onto nitrocellulose using a vacuum spot blot unit 
from Topac (Bristol, United Kingdom).  The membrane was processed using the SNAP i d®. 
Protein Detection System from Millipore (Billerica, MA) following manufacturer’s instructions. 
Briefly, the spotted nitrocellulose was allowed to dry in a 60 degree C oven for 5 minutes.  
Afterwards, the membrane was soaked in 1X PBS and placed on the blot holder, followed by a 
spacer sheet.  The closed blot holder was placed onto the SNAP i.d®. apparatus attached to a 
vacuum.  With the vacuum turned on, 30 mL of I-Block (ThermoFisher Scientific, St. Louis, 
MO) solution (1xPBS, 0.2% I-Block, 0.1% Tween 20) was added to the membrane.  The vacuum 
was turned off before incubating the membrane with 5 mL of I-Block solution containing 10 or 
2µL of the primary antibody, which was mouse anti-bFGF (Santa Cruz biotechnology, Santa 
Cruz, California) or mouse anti-Myc respectively.  After 10 minutes of incubation with the 
primary antibody, the vacuum was turned on again, and the membrane was washed three times 
with a total of 100 mL wash buffer (1X PBS, 0.1% Tween 20).  The membrane was then 
incubated in 5 mL of I-Block containing 25uL of the goat anti-mouse secondary antibody 
(Applied Biosystems, Foster City, CA) for 10 minutes with the vacuum off.  Afterwards, the 
membrane was washed three times with wash buffer again, as previously described, before it was 
incubated for 5 minutes in a petri dish containing 20 mL of femtoLUCENTTM PLUS-AP 1X 
TBST (G-Biosciences, St. Louis, MO).  A flat plastic-wrap surface was prepared where 1-2 mL 
of the femtoLUCENTTM PLUS-AP detection reagent was added dropwise onto the membrane.  
After 5 minutes of incubation at room temperature, the detection reagent was drained off.  The 
membrane was placed into a plastic envelope or wrap and developed using the Bio-Rad 
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ChemiDoc XRS+ Imaging System (Hercules, CA) with exposure times of 3 minutes.  Signals 
were quantified with Bio-Rad ImageLab software.  
Western Blot Analysis 
SDS-PAGE.  20μL of each protein sample was mixed with 4μL of 6x protein sample 
buffer (PSB).  The sample then was heated at 100°C for 10 minutes with Surelocks on. 14% 
Tris-Glycine premade gels from Bio-Rad (Hercules, California) were locked in a running 
apparatus and placed in a running tank containing 1 liter of 1x SDS-PAGE gel running buffer (3 
g/L Tris base, 14 g/L glycine, and 1 g/L SDS).  Each well was washed with the SDS-PAGE 
running buffer to remove any impurities and bubbles.  The heated samples were then spun down 
after they were cooled to room temperature.  20μL of each sample was loaded into its respective 
well as well as 5μL of PageRuler protein ladder from ThermoFisher Scientific (St. Louis, MO). 
The proteins were electrophoresed at 125 V for 50 minutes.  
Membrane transfer.  Once the gel was run, the manufacturer’s instructions for the iBlot 
system (Invitrogen, Carlsbad, California) were followed.  
Detection.  The same steps described for as the spot western blot above were used for 
detection. 
Scratch Assay  
Starving the mammalian cells.  DMEM (starve medium) was warmed up to room 
temperature.  NIH/3T3 cells in 6 well plates are taken out and checked to see if they are 
confluent.  The growth medium was aspirated from each well of the plate. The cells were washed 
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with PBS (2 mL/well).  The PBS was aspirated after that.  2 mL of DMEM was added to each 
well.  The plate was set back into the CO2 37°C incubator for 6 hours.  
Treatments.  Starve: new DMEM (2mL) was added to the its respective well.  10%CS: 
new DMEM+10%CS (2mL) was added to its respective well.  WT cells: 100K P. pastoris 
(yJC100) cells were added to DMEM (2mL) and placed in its respective well.  Hope cells: 100K 
P. pastoris (Hope) cells were added to DMEM (2mL) and placed in its respective well.  The 
plate was incubated again for another 6 hours in the same incubator. 
Scratch.  The plate of wells was taken out and brought into the hood.  A 1000μL pipette 
tip was used to scratch three straight lines in each well from top to bottom.  Under a microscope 
with a camera attached, pictures were taken of the scratches in each well.  Cells were then put 
back into the 37°C CO2incubator for 6 hours.  The plate was then taken out and pictures were 
taken at the same place as the first set of photos to compare how far the cells have moved into 
the scratch.  All images were analyzed using ImageJ program. 
MTS Assay 
The treatments were prepared first.  For starve, new DMEM (50μL) was just added to the 
each appropriate well.  For 10%CS, new DMEM+10%CS (50μL) was just added to each 
appropriate well.  For both Hope and WT conditioned medium, both the strains were grown in 
DMEM for 24 hours in a shaking incubator at 27°C.  Once the cultures were ready, the cultures 
were spun down at 4,000 rmp to form a pellet of yeast at the bottom.  The supernatant was taken 
out and pushed through a sterile filter to get rid of any cells.  The sterile supernatant was then 
used as the conditioned medium.  For the Hope and WT cells, the pellets were resuspended in 
fresh DMEM and the OD was measured for each.  This was used to calculate 10,000 cells to add 
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to the appropriate wells each.  For WT and Hope C+C (conditioned medium + cells), 10K 
cells/well were calculated to add to the conditioned medium.  50μL of each will go into their 
respective wells.  For commercial bFGF or isolated bFGF, 10ng/well would be calculated and 
added into DMEM.  50μL was added to the appropriate wells.  The mammalian cells were taken 
out and used a cell counter to calculate 5,000 cells/50μL.  50μL of mammalian cells were added 
into each well.  The cells proliferated for 24 hours in the 37°C incubator.  The next day, 20μL of 
MTS reagent was added into each well and the plate was then covered in tinfoil.  The plate 
incubated in the 37°C incubator for 2 hours.  The plate was read using a plate reader.  The 
software that recorded the readings was SoftMac Pro.  Two readings were recorded for each 
wavelength: 490 nm and 650 nm.  
Magnetic Myc-bead Purification kit.  
 The manufacturer’s instructions for the ChromoTek Myc-Trap were followed. 
Cation Exchange Purification 
 Appropriate buffers were made beforehand depending on what kind of protein was 
planned on being purified.  The buffers are hooked up to the cation exchange column.  The 
machine washed the loops on its own.  While the machine was being washed, the superloop was 
taken out.  The superloop got filled with the extracellular matrix that the protein trying to be 
purified is in.  The superloop got put back into the machine and the machine ran the exchange.  





Chapter 3: Results 
 The goals of this project were 1) develop a yeast that was capable of producing the 
human growth factor basic fibroblast growth factor (bFGF); 2) co-culture it with mammalian 
cells in order to determine its effects on proliferation and migration, and 3) purify the bFGF 
protein to confirm its cellular activity.  We accomplished the first goal by transforming P. 
pastoris with the coding sequence of bFGF.  The second goal of testing the effects of the yeast 
on mammalian cells was done using scratch and MTS assays.  Lastly, the purification was done 
using cation exchange chromatography and the recombinant protein was tested using the MTS 
assay.  
Construction of the pHML1 Expression Vector 
 The commercially available plasmid pCMV3-Myc-bFGF (Figure 2) contains the bFGF 
coding sequence as well as a c-Myc tag attached to its N-terminus.  The pCMV3-Myc-bFGF was 
transformed into TOP10 cells for the purpose of amplifying the plasmid.  Three colonies were 
grown in LB+Kan liquid media for minipreps the next day.  A miniprep was done to extract and 
purify the plasmid DNA from all three cultures.  Restriction digests were then performed on the 
purified DNA from all three samples digested with KpnI and Xbal restriction enzymes and run 
on an agarose gel electrophoresis to confirm the presence of the pCMV3-Myc-bFGF plasmid. 
The restriction enzymes cut the plasmid to yield two expected bands with sizes 500 bp and 3,000 








Table 1: Sequences for bFGF Forward and Reverse primers to do PCR 
bFGFEcoRI Forward Primer 5’-GGGAATTCACATGGAGCAGAAACTCATC-3’ 




Figure 3: Digested pCMV3-Myc-bFGF using KpnI and Xbal. Lane 1: 1kb plus DNA ladder. 
Lane 2: Sample 1 of digested pCMV3-Myc-bFGF. Lane 3: Sample 2 of digested pCMV3-Myc-




A polymerase chain reaction (PCR) was run using the bFGFEcoRI forward primer and 
bFGFSalI reverse primer (Table 1) to amplify the c-Myc-bFGF coding sequence for subcloning. 
The PCR reaction and the primers (negative controls) were then electrophoresed by agarose gel 
electrophoresis to show the expected PCR product of ~500bp was present (data not shown). 
 To clone the c-Myc-bFGF coding sequence into the vector, pGAPZαB (Figure 4), both 
the PCR product and the pGAPZαB vector were digested with the restriction enzymes EcoRI and 
SalI.  The band sizes for the bFGF PCR and pGAPZαB were ~500 bp and ~3100 bp respectively, 
as seen by agarose gel electrophoresis (Figure 5).  Purified digested vector and insert were mixed 
together and ligated.  The ligation mix pGAPZαB-bFGF was then transformed into STELLAR 
cells and selected on a LB+ZeocinTM (Zeo).  6 transformants were chosen and cultured in 
LB+Zeo liquid medium.  Minipreps were performed, and plasmid DNA was digested with the 
restriction enzymes PstI and BsHtI (AgeI).  The desired plasmid was expected to give the 
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following band sizes: 604 bp and 2962 bp.  An empty pGAPZαB vector was also digested with 
the same enzymes as a negative control (Figure 6).  Agarose gel electrophoresis shows that 
sample 3 contained the correct band lengths while samples 5 and 6 have an extra band at 189 bp. 
Samples 1,2, and 4 have bands at 2962 bp and 189 bp while the negative control only displayed a 
band length at 2962.  Sample 3 was selected to be grown in large quantities in LB+Zeo liquid 
media, and the plasmid found in sample 3 was renamed pHML1 (Figure 7).  pHML1 was 
confirmed that the plasmid contained the DNA sequencing of bFGF in the proper orientation and 
reading frame.  pHML1 contained the c-Myc-bFGF fused in frame to the alpha-factor secretion 
signal, under the control of the constitutive GAP promoter. 
 




Figure 5: Restriction digest of pGAPZαB and bFGF PCR using EcoRI and SalI. Lane 1: 1 kb 





Figure 6: Restriction digest of pGAPZαbFGF from different cultures. Lane 1: 1 kb+ ladder. Lane 
1: pGAPZαB alone as negative control. Lane 2: Sample 1 Lane 3: Sample 2. Lane 4: Sample 3. 











Transformation of pHML1 into P. pastoris 
 To transform the plasmid into competent P. pastoris, pHML1 (pGAPZαbFGF) was 
linearized with the PagI restriction enzyme.  The linearized pHML1 DNA was purified and 
electrophoresed on a gel to show that it was Linearized and had the size of 3566 bp (data not 
shown).  The wild type P. pastoris strain JC100 was transformed with linearized pHML1 by 
electroporation.  Once transformed, the transformants were plated on 8 plates of YPD containing 
increasing concentrations of ZeocinTM (100 μg/mL, 200 μg/mL, 300 μg/mL, 500 μg/mL, and 900 
μg/mL, 1100 μg/mL, 1200 μg/mL, and 1300 μg/mL).  Selection on increasing levels of antibiotic 
usually produces colonies with higher copy numbers of plasmid, which often (but not always) 
leads to higher expression of the recombinant protein encoded by the plasmid.  The number of 
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colonies isolated on each plate are listed in Table 2.  Twenty colonies total from plates 100, 300, 
500, 900, 1200, and 1300 were streaked onto YPD+Zeo plates (100 μg/mL). 
Expression of bFGF 
All the transformed strains are yJC100 Pichia pastoris containing the pHML1 plasmid 
that were selected at a specific concentration of zeocin and denoted by the concentration of 
zeocin for selection.  Thus, the second colony selected from the zeocin plate with 100 μg/mL 
zeocin was yJC100:pHML1-100B or simply called 100B.  20 colonies were then grown in a deep 
well plate (Figure 8) to determine which of the selected colonies were able to synthesize and 
secrete the bFGF growth factor.  Uninoculated medium and a strain containing the empty vector 
were also grown as negative controls.  A strain expressing pDT300, which produces GFP-c-Myc 
from a GAP promoter in high amounts (Li et al., 2010), was also grown as a positive control. 
Cultures were grown for 1 day in BMD and 1 day in BMDY before harvesting.  Equal amounts 
of extracellular medium from each well was then spotted on a spot western and the mouse anti-
Myc primary antibody followed by the goat anti-mouse antibody were used in the detection 
(Figure 9).  Cultures 100B and pDT300 (positive control) showed the strongest signal; however, 
strains 300B, 500B, 500D, 900B, 900D, 1200A, and 1300A also showed some expression of a c-








































100μg/mL 300μg/mL 500μg/mL 900μg/mL 1200μg/mL 1300μg/mL 




 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B   100A   100B   100C  Pos.  
C   300A   300B   300C  pDT  
D   500A   500B   500C  300  
E   500D  Empty  500E   900A   
F   900B  Neg  900C   900D   
G   900E  pGAPZα  1200A   1300A   
H             









Optimization of bFGF production 
 Another deep well plate assay was used to measure the expression of bFGF in different 
media and reassess the level of bFGF expression by the candidate strains.  Eight colonies (100B, 
300B, 500B, 500D, 900B, 900D, 1200A, and 1300A) were grown under three different 
conditions, BMDY pH5, BMDY pH6, and DMEM (Figure 10).  These media were chosen for 2 
reasons: 1) to see if a pH change could improve bFGF secretion in the standard yeast medium 
BMDY, which has been found in other studies (Eissazadeh et al., 2016) and 2) to determine if 
the strains could produce sufficient bFGF in DMEM, a medium in which future co-culturing 
experiments between the recombinant  P.pastoris and mammalian cells will occur.  The positive 
control of pDT300 and negative controls of media only and the negative pGAPZαB-transformed 
strain were also grown in each condition.  The cell density of each sample was then measured 
using a spectrophotometer to see how each medium affected growth (Table 5).  Both the 
BMDYpH5 and pH6 samples grew to a much higher cell density (about three times) than that of 
the cultures grown in DMEM, but the yeast strains still showed significant growth in the tissue 
culture medium.  
A spot western was then conducted on supernatants of the wells using the mouse anti-
Myc primary antibody and goat anti-mouse secondary antibody.  Results for this spot western 
were not consistent because the duplicates did not show the same levels of expression for some 
of the wells (data not shown).  From this spot western, only 100B and 1200A were able to 
express a reliably high level of bFGF in all conditions, and cultures grown in pH5 appeared to be 
more productive than pH6.  
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Western blot analysis were then run to explore and confirm these results (Figure 11 and 
12).  In BMDY medium, thepHML1-transformed yeast produced one bFGF band (size: ~25 
kDa) while multiple, larger molecular weight bFGF bands were secreted in DMEM.  The strain 




 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  100B 100B 300B 300B Pos 100B 100B Pos 300B 300B  
C  500B 500B 500D 500D Pos 500B 500B Pos 500D 500D  
D  900B 900B Neg 900D 900D Neg 900B 900B 900D 900D  
E  1200A 1200A Empty 1300A 1300A Empty 1200A 1200A 1300A 1300A  
F  100B 100B 300B 300B Neg Pos 500B 500B 500D 500D  
G  Empty 900B 900B 900D 900D Pos 1200A 1200A 1300A 1300A  
H             
Figure 10: Growing select colonies in duplicates in different media. Green: BMDY pH5. Orange: 




Table 4: OD reading of the 96 well deep well plate. 100B, 500D, neg, and 1200A of each media. 
Sample Well # OD 
(600nm) 
Sample Well # OD 
(600nm) 
Sample Well # OD 
(600nm) 
100B B2 12.06 100B B7 13.8 100B F3 4.3 
500D C4 12.2 500D C10 13.9 500D F11 4.8 
Neg D4 12.9 Neg D7 12.3 Neg F6 2.5 






    
Figure 11: Western blot analysis of the extracellular matrix of the 96 well deep well plate. pH5 
vs. pH6 Lane 1: PageRuler protein ladder. Lane 2: C6 (pos, GFP-c-Myc). Lane 3: D4 (neg). 






Figure 12: Comparison of bFGF expression in different strains and media. Lane 1: PageRuler 
protein ladder. Lane 2: C6 (BMDY pH5 pos). Lane 3: F7 (DMEM pos). Lane 4: D4 (BMDY 
pH5 neg). Lane 5: F6 (DMEM neg). Lane 6: B7 (BMDY pH5 100B). Lane 7: F2 (DMEM 




 Cell extracts were then made from the twelve cultures (100B, 500D, 1200A, and negative 
from each growing conditions) that were grown in the deep well plate to test how much bFGF 
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was being produced intracellularly, compared to how much was being secreted.  Only BMDY 
pH5 and DMEM cell extracts were electrophoresed on a western blot analysis because cells 
grown in pH5 medium secreted more bFGF than those in pH6 (Figure 13).  The western blot was 
also ran with a positive control of the extracellular matrix (ECM) of a strain producing GFP-c-
Myc.  Along with detecting strong expression from the positive control, the western blot showed 
strong signals from BMDY pH5 100B, but weak signals from BMDY pH5 1200A and DMEM 
100B.  At least 2 bFGF proteins were present within the cells while only 1 bFGF protein was 
detected in the extracellular medium, suggesting the modifications occur to bFGF inside the cell 
during its secretion.  Because strain 100B was the most consistent producer of bFGF both 
intracellularly and extracellularly on different media, we decided to concentrate our using strain 





Figure 13: Western blot analysis of cell extracts from strains cultured in BMDY pH5 vs DMEM. 
Lane 1: PageRuler protein Ladder. Lane 2: P2F6 (pos control, GFP-c-Myc). Lane 3: BMDY pH5 
neg. Lane 4: BMDY pH5 100B. Lane 5: BMDY pH5 500D. Lane 6: BMDY pH5 1200A. Lane 






 Cultures of 100B were then grown under different conditions and for different amounts 
of time in order to find the best conditions to express the Myc-bFGF.  The conditions were 
BMDY pH5, BMDY pH5+FBS, YPD, and BMDY pH5+Methanol+2% glucose. Each ECM 
were collected at 48 hours and 72 hours.  A western blot analysis (Figure 14) was conducted 
using mouse anti-Myc primary antibody and goat anti-mouse secondary antibody with the Hope 
BMDY pH5 from the deep well plate as the positive control.  Hope BMDY pH5 (pos), BMDY 
pH5+FBS 48 hrs, BMDY pH5+FBS 72 hrs, BMDY pH5+Methanol+2% glucose 48 hrs, and 
BMDY pH5+Methanol+2% glucose 72 hrs had very strong signals. BMDY pH5 48 hrs and 
BMDY pH5 72 hrs had weak bands.  The addition of FBS, which is often supplemented to 
DMEM medium, caused the production of higher molecular weight bFGF bands (lanes 5 and 6). 
YPD 48 hrs and YPD 72 hrs did not have any bands.  Thus, we determined that BMDY medium 





Figure 14: Western blot analysis of expressing bFGF in different conditions. Lane 1: PageRuler 
protein ladder. Lane 2: BMDY pH5 (pos). Lane 3: BMDY pH5 48 hrs. Lane 4: BMDY pH5 72 
hrs. Lane 5: BMDY pH5+FBS 48 hrs. Lane 6: BMDY pH5+FBS 72 hrs. Lane 7: YPD 48 hrs. 
Lane 8: YPD 72 hrs. Lane 9: BMDY pH5+Methanol+2% glucose 48 hrs. Lane 10: BMDY 







Magnetic Myc-bead Purification kit.  We first attempted to purify the c-Myc-bFGF 
from ECM of 100B (well B3) and the GFP-c-Myc of pDT600 (well C6) from the deep well plate 
in Figure 10.  This was done by using beads that had a conjugated bFGF antibody.  However, the 
bFGF protein was found in the elution only after boiling the beads (Figure 15) in a western blot 
analysis using an anti-Myc antibody.  Interestingly, which were the 2x Myc peptides, supposed 
to compete the protein off the anti-myc antibody portion of the magnetic bead, but it had no 





Figure 15: Western blot analysis of magnetic Myc-bead purification. Lane 1: Protein ladder. 
Lane2: Positive control P2F7 (GFP-c-Myc). Lane 3: Crude lysate before purification. Lane 4: 





 Cation exchange chromatography.  Because the Myc-magnetic beads purification 
method was unsuccessful, we resorted to using a cation exchange column with a buffer of pH4. 
Because bFGF has a pI of 9.2, it should be highly positively charged in pH4 buffer.  This 
chromatography suggests that the protein would only elute off in high salt-later fractions.  The 
ECM of the 100B strain was loaded onto a cation exchange resin and recombinant proteins were 
eluted off in several fractions of increasing salt concentration.  Using spot western analysis, it 
was found that the strongest signals of bFGF were in fractions 35-43 (Figure 16); these fractions 
(total volume=27 mL) were concentrated down to 500μL using a protein concentrator (molecular 
weight cutoff=10kDa) to create an enriched sample of recombinant bFGF.  A spot western 
analysis was done to determine the amount of bFGF in the enriched sample using commercial 
bFGF at varying concentrations as a standard (Figure 16).  It was estimated that the enriched 
sample’s concentration was about 1ng/μL of bFGF.  Based on this quantitation, we were able to 
use approximately the same amount of this enriched bFGF as the commercial bFGF to compare 




Figure 16: Spot western of cation exchange fractions along with the Hope’s ECM as a positive 




 In a western blot analysis, the bFGF was shown to be concentrated from its initial levels 
in the starting ECM (lane 3) to its level in fraction 38 (lane 5) and in the enriched concentrated 
sample (lane 6) (Figure 17).  As shown by SDS-PAGE analysis and silver staining, the enriched 
bFGF was fairly concentrated and a lot purer than it was before (Figure 16B). It went from 624 
mg of total protein in the starting ECM (Lane 3) to 1.08 mg of protein in the enriched fraction 










B)   
Figure 17: A) Western blot analysis of the cation exchange fractions. Lane 1: PageRuler protein 
ladder. Lane 2: commercial bFGF as a positive control (100 ng). Lane 3: Hope’s ECM. Lane 4: 
Fraction 10 (negative control). Lane 5: unconcentrated fraction 38. Lane 6: concentrated 
fractions 35-43 (enriched bFGF). Lane 7: Flow through of concentrator. B)Silver stain of the 
fractions from the cation exchange. Lane 1: PageRuler protein ladder. Lane 2: commercial bFGF 
(positive contrl,100ng). Lane 3: 100B ECM before cation exchange. Lane 4: Fraction 11 
(negative control) Lane 5: Fraction 38 (highest signal in Figure 16). Lane 6: Enriched bFGF 







Figure 18: Spot western of commercial bFGF and enriched bFGF from the cation exchange 
chromatograhy. Top row: commercial bFGF concentrations (20ng, 15ng, 10ng, and 5ng). Bottom 





MTS assay.  An MTS assay, which measures cell proliferation, was conducted with 
5,000 NIH/3T3 cells in each colored well with different treatments (Figure 19) in order to 
determine the effects of the different treatments compared to the commercial bFGF, which is 
made in bacteria.  NIH/3T3 cells were grown in the presence of DMEM supplemented with 
nothing (starve) or with chemicals (10%CS, commercial bFGF, enriched bFGF), conditioned 
extracellular medium from yeast cells, yeast cells, or combination of conditioned extracellular 
medium from yeast cells and the yeast cells (C+C).  There were three negative controls, which 
contained no NIH/3T3 cells, designated as “only”. Conditioned medium is DMEM based where 
the yeast have grown for 24 hours before sterile filtering.  Thus, this medium was used only for 
the assay.  The Hope conditioned media was also spotted on a spot western alongside known 
concentrations of commercial bFGF to measure the concentration of bFGF produced by Hope P. 
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pastoris cells in the conditioned media (Figure 20).  It was found that the concentration of bFGF 
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Figure 19: 96 well plate with 5K NIH/3T3 cells in each well with a treatment. Starve: Cell 
treatment with DMEM only. 10% CS: Cell treatment with DMEM+10% calf serum. bFGF: Cell 
treatment with DMEM+10ng commercial bFGF. WT cond.: Wild type conditioned media, Cell 
treatment with DMEM that WT was growing in for 24 hours and then had the yeast taken out.. 
Hope cond.: Hope conditioned media, Cell treatment with DMEM that Hope was growing in for 
24 hours and then had the yeast taken out. Enriched bFGF: Cell treatment with 10ng of enriched 
bFGF in DMEM. WT C+C: Cell treatment with WT conditioned media and 10,000 WT yeast 
cells added in DMEM. Hope C+C: Cell treatment with Hope conditioned media and 10,000 
Hope yeast cells added in DMEM. WT cells: Cell treatment with only 10,000 WT yeast cells in 
DMEM. Hope cells: Cell treatment with only 10,000 Hope yeast cells in DMEM. Starve only: 
DMEM only with no cells. WT cells only: 10,000 WT cells in DMEM with no 3T3 cells. Hope 







Figure 20: Spot western to estimate bFGF concentration in the Hope conditioned medium. Top 
row: commercial bFGF concentrations (20ng, 15ng, 10ng, and 5ng). Bottom row: Hope 
conditioned media volumes (200μL, 100μL, 50μL, and 25μL). 
 
The results of the MTS assay (Tables 5 and 6, Figures 21 and 22) show that 10% CS 
helped the NIH/3T3 cells proliferate greatest compared to cells treated with starve medium 
(DMEM only). Commercial bFGF (0.1ng/μL) did the second best with about an 80% increase of 
proliferation compared to that of starve.  Hope conditioned media (0.04ng/μL), enriched bFGF 
(0.1ng/μL), and Hope C+C gave about the same effect (~60% increase of proliferation compared 
to starve medium) when it came to accelerating the proliferation of the NIH/3T3 cells.  WT 
conditioned media, WT C+C, WT cells and Hope cells all helped proliferation slightly (~10% 
increase) more than the starve medium.  Thus, the Hope cells alone did not cause the same 









Table 5: The average absorbance of each treatment in 490nm and 650 nm (normalize) along with 
the difference in the two readings and the standard deviation.   




Starve 0.2530 0.0429 0.2101 0.0111 
10% CS 0.5215 0.0800 0.4416 0.0521 
Commercial 
bFGF 
0.4413 0.0540 0.3873 0.0306 
WT Cond 0.2762 0.0450 0.2312 0.0157 
Hope Cond 0.3826 0.0520 0.3306 0.0351 
Enriched FGF 0.3890 0.0552 0.3338 0.0225 
WT C+C 0.2800 0.0466 0.2334 0.0212 
Hope C+C 0.4019 0.0558 0.3461 0.0315 
WT Cells 0.2767 0.0467 0.2300 0.0204 
Hope Cells 0.2761 0.0473 0.2288 0.0179 
Starve alone 0.1424 0.0390 0.1034 0.0006 
WT alone 0.1413 0.0398 0.1015 0.0023 





































Table: 6: % difference in proliferation of NIH/3T3 cells compared to NIH/3T3 cells in starve 
medium alone (baseline) 
 % difference from starve 
Starve 0.00 
10% CS 110.17 
Commercial bFGF 84.36 
WT Cond 10.05 
Hope Cond 57.35 
Enriched bFGF 58.87 
WT C+C 11.07 
Hope C+C 64.75 
WT Cells 9.47 









            Scratch Assay.  The scratch assay was conducted using different treatments like that of 
the MTS assay.  The treatments were starve (DMEM only), 10% CS (DMEM+10% calf serum), 
bFGF (10ng of commercial bFGF in DMEM), WT (wild type, untransformed P. pastoris co-
cultured with the NIH/3T3 cells in DMEM), Hope (Hope cells co-cultured with the NIH/3T3 








% difference from starve 
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taken out), and Hope conditioned media (Hope grown in DMEM for 24 hours and had the yeast 
taken out).  The scratch assay showed that 10% CS affected the mammalian cells the most by 
having the cells migrate into the scratch 25% of the way in 5 hours.  Conditioned Hope media 
had the same effect as Hope cells, but the NIH/3T3 cells only moved in ~10% of the scratch.  
WT helped the cells migrate about 3% into the scratch. Lastly, both starve and WT conditioned 
media helped the cells migrate very little (Table 7 and Figure 23).  This assay shows that Hope is 




Table 7: The scratch assay with different treatments. Listed are how wide the initial scratch was 
at the start and after 5 hours of treatment. The  difference is taken and the percent change is 
calculated.  
 start 5 hours difference % change 
Starve 75.6 74.5 1.1 1.5% 
10% CS 78.8 58.9 19.9 25.3% 
Hope cond. 79.2 70.4 8.9 11.2% 
WT cond. 72.0 71.8 0.2 0.3% 
Hope cells 114 103.6 10.4 9.1% 












            JNK is a downstream target that gets activated by phosphorylation during cell motility 
when bFGF binds a bFGFR (bFGF receptor).  High levels of phosphorylated JNK correlates to 
cell motility so we expected to see high levels of pJNK in the samples where the cells were 
treated with some form of bFGF (commercial or Hope).  The 5 treatments used were starve 
(DMEM only), 10% CS (DMEM+10% calf serum), bFGF (10ng of commercial bFGF in 
DMEM), Hope conditioned media (DMEM that had Hope growing in it for 24 hours and then 
had the yeast removed through sterile filter), and WT conditioned media (DMEM that had WT 
growing in it for 24 hours and then had the yeast removed through sterile filter).  A GAPDH 
western blot analysis was performed to ensure equal loading and all the data were normalized to 
GAPDH signal to compare levels of JNK and pJNK.  The JNK level checked against the pJNK 
level in western blot analysis confirm that the rise in pJNK was not form having more JNK to 
begin with.  Based on signals normalized to GAPDH (Figure 24), JNK levels were roughly equal 


















bFGF, and Hope conditioned medium treatments caused an increased amount of phosphorylated 






Figure 24: Western blot analysis with anti-GAPDH antibody: Lane 1: PageRuler protein ladder. 
Lane 2: Starve. Lane 3: 10% CS. Lane 4: WT conditioned medium. Lane 5: commercial bFGF. 







Figure 25: Western blot analysis with anti-JNK antibody: Lane 1: PageRuler protein ladder. Lane 
2: Starve. Lane 3: 10% CS. Lane 4: WT conditioned medium. Lane 5: commercial bFGF. Lane 





Figure 26: Western blot analysis with anti-pJNK antibody: Lane 1: PageRuler protein ladder. 
Lane 2: Starve. Lane 3: 10% CS. Lane 4: WT conditioned medium. Lane 5: commercial bFGF. 
Lane 6: Hope conditioned medium. The numbers underneath each box represents how much 






Table 8: Ratio of p-JNK to JNK 
 Starve 10%CS WT Commercial 
bFGF 
Hope 

















Chapter 4: Discussion 
 Accelerating the healing of wounds inside the mouth is a difficult task.  Because the 
constant production of saliva will wash away any medicinal ointment placed on the site of injury. 
A possible solution could be placing a microbe that will attach onto the injured site in order to 
constitutively express and secrete a growth factor to promote healing of the damaged tissue. 
Such microbes, which have been developed previously for the treatment of intestinal diseases, 
are known as engineered probiotics (Steidler, 2003). Many of these probiotics, like 
Saccharomyces boulardii, have not been studied enough to easily genetically modify the yeast. 
Pichia pastoris, on the other hand, has been studied for many years and techniques have been 
developed to genetically modify this yeast.  Not only that, but P. pastoris is a great recombinant 
protein expressor.  Past studies have found it possible to make a strain of P. pastoris that is able 
to express bFGF that has a regenerative effect on the NIH/3T3 mouse fibroblast cells (Mu et al., 
2007).  This strain had the bFGF DNA coding sequence under the control of the methanol 
induced promoter, AOX1 (alcohol oxidase), so the bFGF was not expressed constitutively.  In 
this project, we have also selected the yeast, Pichia pastoris, to make and secrete the basic 
fibroblast growth factor (bFGF) constitutively using the GAP (glyceraldehyde-3-phosphate 
dehydrogenase) promoter since the yeast would need to produce bFGF in the mouth in the future. 
We hypothesized the bFGF secreted by our recombinant strain of P. pastoris will increase both 
migration and proliferation of NIH/3T3 mouse fibroblast cells. In this study, the recombinant 
bFGF’s effects on migration were tested on scratch assays where a plate of NIH/3T3 cells is 
scratched and the migration of the cells into the scratch is observed.  The effects of the 
recombinant bFGF on proliferation were tested in MTS assays where equal numbers of NIH/3T3 




 We originally tried a magnetic Myc-bead purification, but we were only able to elute the 
protein off the beads by denaturing the bFGF protein in a 100°C heat block.  This was not useful 
because we needed functional protein to test in our scratch and MTS assays.  Using the Myc 
peptides from Chromotek (München, Germany) as a competitor to elute our protein did not work 
because the c-Myc-bFGF was bound onto the magnetic beads too strongly and the Myc peptides 
had a hard time competing the bFGF protein off.  This left us with having to perform a cation 
exchange chromatography to purify our recombinant protein.  Because other proteins eluted off 
of the resin with the bFGF, the fractions were not pure bFGF.  However, it became enriched to a 
high degree after concentrating the proteins from fractions 35-43.  The 60 mL of ECM used in 
the cation exchange went from 624mg of total protein to just 1.08mg in the enriched fraction.  
Functional Activity Studies 
 The MTS showed that the proliferation of the NIH/3T3 cells had been positively affected 
by the Hope strain’s recombinant bFGF whether it was present in the conditioned media or as the 
isolated/concentrated protein.  As controls, starved medium and the yeast cells alone did not 
increase absorbance in the MTS assay.  The starved media was used as a baseline control to see 
how the cells would grow with just DMEM, which contained just the essentials to live.  The 10% 
CS contained growth factors and hormones in it so it was expected to have the highest 
proliferation rate (>100% growth increase compared to DMEM).  The enriched bFGF, Hope 
conditioned medium, Hope conditioned medium with P. pastoris, and commercial bFGF all 
displayed about the same amount of proliferation (~60% growth increase compared to DMEM). 
The wild type (WT) conditioned medium (from untransformed Pichia pastoris cells), WT 
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conditioned medium with P. pastoris, WT cells, and Hope cells showed about the same growth 
as just DMEM (~10% growth increase), meaning, they had little effect on the mammalian cell 
proliferation.  While the Hope conditioned medium and Hope conditioned medium with P. 
pastoris induced a large increase in proliferation, the Hope cells showed little effect on the 
NIH/3T3 cells, which suggested that the Hope strain was not producing enough of the bFGF in 
the 24-hour window that the MTS assay lasted.  This could be because there was not enough of 
the bFGF producing yeast in the assay to make sufficient bFGF to have an effect.  This co-
culturing to improve the effects of proliferation will need to be repeated with a higher 
concentration of Hope cells.  The scratch assays showed that the Hope medium (both 
conditioned and with the cells) induced migration compared to that of the WT and starve 
(baseline).  This is promising because the migration of cells is essential wound healing.  
 Throughout the project, the bFGF found made by the Hope strain was always found to be 
heavier than what bFGF’s predicted mass.  A possible reason is that it has some additional post 
translational modifications such as glycosylation, which would not be found on the bacterially-
produced commercial bFGF.  Even though the protein is heavier than the commercial bFGF, the 
activity of the recombinant bFGF is not hindered by it.  The recombinant bFGF works almost as 
as well at the commercial bFGF in the MTS assay. 
 Migration of fibroblast cells is very important because they are involved in the wound 
healing.  It has been shown that the activation of the protein JNK by phosphorylation is essential 
to a cell’s movement (Kanazawa,2010).  This correlation was observed in our western blots.  The 
treatments that helped the cells migrate faster, such as conditioned Hope medium, were 
associated with higher levels of phosphorylated JNK than the treatments that did not help the 
NIH/3T3 cells migrate.  This shows that P. pastoris made bFGF does trigger the cascade to 
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activate or phosphorylate the JNK in order for the NIH/3T3 cell to migrate just like the 
commercial bFGF.  
Future Work 
As stated; before in the MTS assay, the Hope strain co-culture did not produce a 
significant effect on the growth of NIH/3T3 cells.  This could be due to the fact that there were 
not enough of the yeast in the well to make sufficient bFGF to see an effect.  Co-culturing with 
NIH/3T3 cells will have to be optimized so that a high amount of bFGF is released by the Hope 
cells. 
Another limitation of this project was in our early work that the human cell lines were 
difficult to grow and maintain for the activity assays.  We had to resort to using mouse fibroblast 
cells (NIH/3T3) cells, as in the Mu et al., 2007 study.  Now that it has been shown that the bFGF 
secreted from the Hope strain can positively affect the proliferation and migration of mouse 
fibroblast cells, the experiments can be repeated on more relevant human tissue culture cells such 
as human dental pulp cells.  Both the MTS and scratch assays should be used to determine how 
the recombinant bFGF will affect the human cells. 
Another idea for future work could be to improve the bFGF production in the yeast 
through mutating the Matα secretion signal to enhance the secretion.  Multiple copies of the 
plasmid transformed into P. pastoris would be expected to give higher protein secretion (Aw, 
Polizzi, 2013), but it seemed like the more copies it had (higher zeocin resistance), the less 
efficient it was at expressing the bFGF protein.  A possible reason could be that the cell is 
making too much bFGF to secrete out efficiently, causing a “traffic jam” of the recombinant 




 This study has allowed us to make a strain of Pichia pastoris that is able to express and 
secrete bFGF.  The bFGF made has been observed to cause a positive effect on mouse cells’ 
migration and proliferation.  There is great potential with this project.  With further 
improvements, modifications, and testing, a P. pastoris product can one day exist for dentist to 
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